Some Products May Appear Restricted
To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.
If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/us/en/login/register)
If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation; additional documentation will be requested for these items prior to shipment.
Specifications
- Size:100 Assays
- Cat. No.:103010-172
- Storage temperature:– 20 °C
- Includes:The assays can be performed in a convenient 96-well microplate format, kit includes essential components and detailed protocol and references
- Supplier no.:AS-71144
Specifications
About this item
β-Secretase is a membrane-anchored aspartic protease existing in acidic subcellular vesicles
The SensoLyte® 520 β-Secretase Assay Kit is a homogeneous assay that can be used to detect the activity of enzyme and for screening of secretase inhibitors. It contains a QXL® 520/ HiLyte™ Fluor 488 FRET substrate. The sequence of this FRET peptide is derived from the β-secretase cleavage site on the Swedish APP mutation. This mutation causes the enhancement of β-secretase to process APP, resulting in an early onset of AD. Active β-secretase cleaves FRET substrate into two separate fragments resulting in the release of HiLyte™ Fluor 488 fluorescence that can be monitored at excitation/emission= 490/520 nm. The long wavelength fluorescence of HiLyte™ Fluor 488 is less interfered by the autofluorescence of components in biological samples and test compounds.
It is a key player in producing β-amyloid peptides through proteolytic cleavage of the β-amyloid precursor protein (APP). Accumulation of neurotoxic β-amyloid peptide is seen in senile plaques in the brains of patients with Alzheimer’s disease (AD), an age-related cognitive disorder. Therefore, targeting β-secretase is considered a potential therapeutic strategy for the prevention and treatment of AD.